EXPEDITED REVIEW
Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
Deepak L. Bhatt, MD, FACC*,*,
Marcus D. Flather, MD ,
Werner Hacke, MD ,
Peter B. Berger, MD, FACC ,
Henry R. Black, MD||,
William E. Boden, MD, FACC¶,
Patrice Cacoub, MD#,
Eric A. Cohen, MD**,
Mark A. Creager, MD, FACC,
J. Donald Easton, MD,
Christian W. Hamm, MD, FACC,
Graeme J. Hankey, MD||||,
S. Claiborne Johnston, MD, PhD¶¶,
Koon-Hou Mak, MD, FACC##,
Jean-Louis Mas, MD***,
Gilles Montalescot, MD, PhD,
Thomas A. Pearson, MD, FACC,
P. Gabriel Steg, MD, FACC,
Steven R. Steinhubl, MD, FACC||||||,
Michael A. Weber, MD, FACC¶¶¶,
Liz Fabry-Ribaudo, MSN, RN*,
Tingfei Hu, MS*,
Eric J. Topol, MD, FACC### and
Keith A.A. Fox, MBChB**** for the CHARISMA Investigators
* Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio
Clinical Trials and Evaluation Unit, Royal Brompton Hospital, London, United Kingdom
Department of Neurology, University of Heidelberg, Heidelberg, Germany
Geisinger Center for Health Research, Danville, Pennsylvania
|| New York University School of Medicine, New York, New York
¶ Division of Cardiology, Kaleida Healthcare, Buffalo, New York
# Department of Internal Medicine, Hopital Pitie-Salpetriere, Paris, France
** Division of Cardiology, Sunnybrook and Women's College Health Science Centre, Toronto, Canada
Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
Department of Neurology, Rhode Island Hospital and Brown University, Providence, Rhode Island
Department of Cardiology, Kerckhoff-Klinik Center, Bad Nauheim, Germany
|||| Department of Neurology, Royal Perth Hospital and School of Medicine and Pharmacology, The University of Western Australia, Perth, Australia
¶¶ Department of Neurology, University of California San Francisco, San Francisco, California
## Gleneagles Medical Centre, Singapore
*** Department of Neurology and Stroke Unit, Sainte-Anne Hospital, Paris, France
Institut de Cardiologie — Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
Department of Community & Preventive Medicine, University of Rochester School of Medicine, Rochester, New York
Service de Cardiologie, Hôpital Bichat, Paris, France
|||||| Division of Cardiology, University of Kentucky, Lexington, Kentucky
¶¶¶ SUNY Downstate Medical Center College of Medicine, Brooklyn, New York
### Case Western Reserve University, Cleveland, Ohio
**** University and Royal Infirmary of Edinburgh, Edinburgh, United Kingdom.
Manuscript received December 4, 2006;
revised manuscript received March 16, 2007,
accepted March 20, 2007.
* Reprint requests and correspondence: Dr. Deepak L. Bhatt, Associate Director, Cardiovascular Coordinating Center, Staff, Cardiac, Peripheral, and Carotid Intervention, Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195. (Email: bhattd{at}ccf.org).
Objectives: The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD).
Background: Dual antiplatelet therapy with clopidogrel plus aspirin has been validated in the settings of acute coronary syndromes and coronary stenting. The value of this combination was recently evaluated in the CHARISMA (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance) trial, where no statistically significant benefit was found in the overall broad population of stable patients studied.
Methods: We identified the subgroup in the CHARISMA trial who were enrolled with documented prior MI, ischemic stroke, or symptomatic PAD.
Results: A total of 9,478 patients met the inclusion criteria for this analysis. The median duration of follow-up was 27.6 months. The rate of cardiovascular death, MI, or stroke was significantly lower in the clopidogrel plus aspirin arm than in the placebo plus aspirin arm: 7.3% versus 8.8% (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.72 to 0.96, p = 0.01). Additionally, hospitalizations for ischemia were significantly decreased, 11.4% versus 13.2% (HR 0.86, 95% CI 0.76 to 0.96, p = 0.008). There was no significant difference in the rate of severe bleeding: 1.7% versus 1.5% (HR 1.12, 95% CI 0.81 to 1.53, p = 0.50); moderate bleeding was significantly increased: 2.0% versus 1.3% (HR 1.60, 95% CI 1.16 to 2.20, p = 0.004).
Conclusions: In this analysis of the CHARISMA trial, the large number of patients with documented prior MI, ischemic stroke, or symptomatic PAD appeared to derive significant benefit from dual antiplatelet therapy with clopidogrel plus aspirin. Such patients may benefit from intensification of antithrombotic therapy beyond aspirin alone, a concept that future trials will need to validate. (Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA]; http://clinicaltrials.gov/ct/show/NCT00050817?order=1; NCT00050817
[ClinicalTrials.gov]
)
|
Abbreviations and Acronyms
| | CI = confidence interval | | HR = hazard ratio | | MI = myocardial infarction | | PAD = peripheral arterial disease |
|
This article has been cited by other articles:
|
|
|
|
 
J. Saw, E. H. Madsen, S. Chan, and E. Maurer-Spurej
The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) Study
J. Am. Coll. Cardiol.,
December 2, 2008;
52(23):
1826 - 1833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Husted
Benefits and risks with antiplatelet therapy: how great a problem is bleeding?
Eur. Heart J. Suppl.,
November 1, 2008;
10(suppl_I):
I19 - I24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. B. King III and E. L. Hannan
Mounting Evidence for Safety and Improved Outcomes of Drug-Eluting Stenting: But Is It the Stent?
Circulation,
October 28, 2008;
118(18):
1783 - 1784.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. W. Eikelboom, G. J. Hankey, J. Thom, D. L. Bhatt, P. G. Steg, G. Montalescot, S. C. Johnston, S. R. Steinhubl, K.-H. Mak, J. D. Easton, et al.
Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk
Circulation,
October 21, 2008;
118(17):
1705 - 1712.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. H. Shishehbor, S. S. Goel, S. R. Kapadia, D. L. Bhatt, P. Kelly, R. E. Raymond, J. M. Galla, S. J. Brener, P. L. Whitlow, and S. G. Ellis
Long-Term Impact of Drug-Eluting Stents Versus Bare-Metal Stents on All-Cause Mortality
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1041 - 1048.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sullivan and N. Amarshi
Dual antiplatelet therapy with clopidogrel and aspirin
Am. J. Health Syst. Pharm.,
June 15, 2008;
65(12):
1134 - 1143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington
The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
776S - 814S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Y. Gasparyan, T. Watson, and G. Y.H. Lip
The Role of Aspirin in Cardiovascular Prevention: Implications of Aspirin Resistance
J. Am. Coll. Cardiol.,
May 13, 2008;
51(19):
1829 - 1843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Thijs, R. Lemmens, and S. Fieuws
Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke
Eur. Heart J.,
May 1, 2008;
29(9):
1086 - 1092.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. O'Donnell, G. J. Hankey, and J. W. Eikelboom
Antiplatelet Therapy for Secondary Prevention of Noncardioembolic Ischemic Stroke: A Critical Review
Stroke,
May 1, 2008;
39(5):
1638 - 1646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. R. BAKHRU and D. L. BHATT
INTERPRETING THE CHARISMA STUDY: What is the role of dual antiplatelet therapy with clopidogrel and aspirin?
Cleveland Clinic Journal of Medicine,
April 1, 2008;
75(4):
289 - 295.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sanz, P. R. Moreno, and V. Fuster
The year in atherothrombosis.
J. Am. Coll. Cardiol.,
March 4, 2008;
51(9):
944 - 955.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Wittgen
Limb Ischemia: Medical Therapy Trial Update
Perspectives in Vascular Surgery and Endovascular Therapy,
March 1, 2008;
20(1):
38 - 42.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F. M. Gengo, M. Rainka, M. Robson, M. F. Gengo, A. Forrest, M. Hourihane, and V. Bates
Prevalence of Platelet Nonresponsiveness to Aspirin in Patients Treated for Secondary Stroke Prophylaxis and in Patients With Recurrent Ischemic Events
J. Clin. Pharmacol.,
March 1, 2008;
48(3):
335 - 343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Bhatt
Intensifying Platelet Inhibition -- Navigating between Scylla and Charybdis
N. Engl. J. Med.,
November 15, 2007;
357(20):
2078 - 2081.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Gebel Jr.
The CAPRIE-Like Subgroups of CHARISMA: A CAPRIEciously Biased Analysis of an unCHARISMAtic Truth
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1704 - 1704.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. L. Bhatt, M. D. Flather, and on behalf of the CHARISMA Executive Committee and
Reply
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1704 - 1705.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. H. Wang, D. L. Bhatt, K. A.A. Fox, S. R. Steinhubl, D. M. Brennan, W. Hacke, K.-H. Mak, T. A. Pearson, W. E. Boden, P. G. Steg, et al.
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
Eur. Heart J.,
September 2, 2007;
28(18):
2200 - 2207.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Bavry and D. L. Bhatt
Drug-Eluting Stents: Dual Antiplatelet Therapy for Every Survivor?
Circulation,
August 14, 2007;
116(7):
696 - 699.
[Full Text]
[PDF]
|
|
|
|
